



Featured Stocks in January's Most Attractive/Most Dangerous Model Portfolios

Recap From December's Picks

Our Most Attractive Stocks (+2.2%) underperformed the S&P 500 (+4.8%) from December 2, 2021 through January 3, 2022 by 2.6%. The best performing large cap stock gained 11% and the best performing small cap stock was up 16%. Overall, 13 out of the 40 Most Attractive stocks outperformed the S&P 500.

Our Most Dangerous Stocks (+2.1%) outperformed the S&P 500 (+4.8%) as a short portfolio from December 2, 2021 through January 3, 2022 by 2.7%. The best performing large cap short stock fell by 17% and the best performing small cap short stock fell by 22%. Overall, 23 out of the 38 Most Dangerous stocks outperformed the S&P 500 as shorts.

The Most Attractive/Most Dangerous Model Portfolios outperformed as an equal-weighted long/short portfolio by 0.1%.

Buy the
Most Attractive Stocks Model Portfolio
for January

Buy the
Most Dangerous Stocks Model Portfolio
for January

More [reliable](#) & [proprietary](#) fundamental data, proven in [The Journal of Financial Economics](#), drives our research and provides investors with a [new source of alpha](#). Our proprietary [Robo-Analyst Technology](#)¹ scales our forensic accounting expertise ([featured in Barron's](#)) across thousands of stocks² to produce an unrivaled database of fundamental data.

Six new stocks make our Most Attractive list this month, and four new stocks fall onto the Most Dangerous list. January's Most Attractive and Most Dangerous stocks were made available to members on January 5, 2022.

Our Most Attractive stocks all share a high and rising return on invested capital (ROIC) and low [price to economic book value ratio](#). Most Dangerous stocks have [misleading earnings](#) and long [growth appreciation periods](#) implied by their market valuations.

Most Attractive Stocks Feature for January: Hillenbrand Inc. (HI: \$51/share)

Hillenbrand Inc. (HI) is the featured stock from January's [Most Attractive Stocks Model Portfolio](#).

Hillenbrand has grown revenue by 13% compounded annually and net operating profit after-tax (NOPAT) by 17% compounded annually over the past five years.


The company's NOPAT margin increased from 10% in fiscal 2016 (FYE is 9/30) to 12% in fiscal 2021, while [invested capital turns](#) rose from 0.86 to 0.94 over the same period. Rising margins and improved invested capital turns drove Hillenbrand's ROIC from 9% in fiscal 2016 to 11% in fiscal 2021.

¹ Harvard Business School features our research automation technology in the case [Disrupting Fundamental Analysis with Robo-Analysts](#).

² See how our models overcome flaws in Bloomberg and Capital IQ's (SPGI) analytics in the [detailed appendix of this paper](#).



Figure 1: Revenue & NOPAT Since Fiscal 2016



Sources: New Constructs, LLC and company filings

Hillenbrand Is Undervalued

At its current price of \$51/share, HI has a price-to-economic book value ([PEBV](#)) ratio of 0.8. This ratio means the market expects Hillenbrand’s NOPAT to permanently decline by 20%. This expectation seems overly pessimistic for a company that has grown NOPAT by 11% compounded annually over the past decade.

Even if Hillenbrand’s NOPAT margin falls to 11% (equal to three-year average, compared to 12% in fiscal 2021) and the company’s NOPAT grows by just 2% compounded annually for the next decade, the stock is worth \$68/share today – a 33% upside. [See the math behind this reverse DCF scenario](#). Should Hillenbrand grow profits more in line with historical levels, the stock has even more upside.

Critical Details Found in Financial Filings by Our [Robo-Analyst Technology](#)

Below are specifics on the adjustments we make based on Robo-Analyst findings in Hillenbrand’s 10-K:

Income Statement: we made \$229 million in adjustments, with a net effect of removing \$85 million in [non-operating expenses](#) (3% of revenue). You can see all the adjustments made to Hillenbrand’s income statement [here](#).

Balance Sheet: we made \$796 million in adjustments to calculate invested capital with a net increase of \$22 million. One of the most notable adjustments was \$190 million in [asset write-downs](#). This adjustment represented 6% of reported net assets. You can see all the adjustments made to Hillenbrand’s balance sheet [here](#).

Valuation: we made \$2.1 billion of adjustments with a net effect of decreasing shareholder value by \$1.4 billion. One of the most notable adjustments to shareholder value was \$303 million in [excess cash](#). This adjustment represents 4% of Hillenbrand’s market cap. See all adjustments to Hillenbrand’s valuation [here](#).


Most Dangerous Stocks Feature: NeoGenomics, Inc. (NEO: \$25/share)

NeoGenomics, Inc. (NEO) is the featured stock from January’s [Most Dangerous Stocks Model Portfolio](#).

NeoGenomics’s [economic earnings](#), the true cash flows of the business, fell from -\$4 million in 2015 to -\$100 million over the trailing-twelve-months (TTM). The company’s NOPAT margin fell from 0% in 2015 to -8% TTM, while ROIC fell from -1% to -4% over the same time.



Figure 2: Economic Earnings Since 2015



Sources: New Constructs, LLC and company filings

NeoGenomics Provides Poor Risk/Reward

Despite its poor fundamentals, NeoGenomics is priced for significant profit growth, and we believe the stock is overvalued.

To justify its current price of \$25/share, NeoGenomics must improve its NOPAT margin to 5% (all-time high compared to -8% TTM) and grow revenue by 28% compounded annually for the next decade. [See the math behind this reverse DCF scenario.](#) In this scenario, NeoGenomics NOPAT in 2030 equals \$240 million. Given that NeoGenomics’s NOPAT fell from \$19 million in 2019 to -\$37 million over the TTM, we think these expectations are overly optimistic.

Even if NeoGenomics can achieve a NOPAT margin of 5% and grow revenue by 15% compounded annually for the next decade, the stock is worth just \$7/share today – a 72% downside to the current stock price. [See the math behind this reverse DCF scenario.](#) Should NeoGenomics’s revenue grow at a slower rate or NOPAT margins not recover to 2013 levels, the stock has even more downside.

Each of these scenarios also assumes NeoGenomics can grow revenue, NOPAT, and FCF without increasing working capital or fixed assets. This assumption is unlikely but allows us to create truly best-case scenarios that demonstrate how high expectations embedded in the current valuation are.

Critical Details Found in Financial Filings by Our [Robo-Analyst Technology](#)

Below are specifics on the adjustments we make based on Robo-Analyst findings in NeoGenomics’s 10-K and 10-Qs:

Income Statement: we made \$43 million in adjustments, with a net effect of removing \$11 million in [non-operating income](#) (2% of revenue). You can see all the adjustments made to NeoGenomics’s income statement [here](#).

Balance Sheet: we made \$300 million in adjustments to calculate invested capital with a net decrease of \$285 million. One of the most notable adjustments was \$5 million in [asset write-downs](#). This adjustment represented <1% of reported net assets. You can see all the adjustments made to NeoGenomics’s balance sheet [here](#).

Valuation: we made \$1.0 billion in adjustments, with a net decrease to shareholder value of \$379 million. Apart from [total debt](#), the most notable adjustment to shareholder value was \$316 million in [excess cash](#). This adjustment represents 10% of NeoGenomics’s market cap. See all adjustments to NeoGenomics’s valuation [here](#).



This article originally published on [January 14, 2022](#).

Disclosure: David Trainer, Kyle Guske II, and Matt Shuler receive no compensation to write about any specific stock, style, or theme.

Follow us on [Twitter](#), [Facebook](#), [LinkedIn](#), and [StockTwits](#) for real-time alerts on all our research.



It's Official: We Offer the Best Fundamental Data in the World

Many firms claim their research is superior, but none of them can prove it with independent studies from highly-respected institutions as we can. Three different papers from both the public and private sectors show:

1. Legacy fundamental datasets suffer from significant inaccuracies, omissions and biases.
2. Only our “novel database” enables investors to overcome these flaws and apply [reliable](#) fundamental data in their research.
3. Our proprietary measures of [Core Earnings](#) and [Earnings Distortion](#) materially improve stock picking and forecasting of profits.

Best Fundamental Data in the World

Forthcoming in [The Journal of Financial Economics](#), a top peer-reviewed journal, [Core Earnings: New Data & Evidence](#) proves our Robo-Analyst technology overcomes material shortcomings in legacy firms’ data collection processes to provide superior [fundamental data](#), [earnings](#) models, and [research](#). More [details](#).

Key quotes from the paper:

- “[New Constructs’] *Total Adjustments* differs significantly from the items identified and excluded from Compustat’s adjusted earnings measures. For example... 50% to 70% of the variation in *Total Adjustments* is not explained by S&P Global’s (*SPGI*) *Adjustments* individually.” – pp. 14, 1st para.
- “A final source of differences [between New Constructs’ and S&P Global’s data] is due to data collection oversights...we identified cases where Compustat did not collect information relating to firms’ income that is useful in assessing core earnings.” – pp. 16, 2nd para.

Superior Models

A top accounting firm features the superiority of our ROIC, NOPAT and Invested Capital research to Capital IQ & Bloomberg’s in [Getting ROIC Right](#). See the [Appendix](#) for direct comparison details.

Key quotes from the paper:

- “...an accurate calculation of ROIC requires more diligence than often occurs in some of the common, off-the-shelf ROIC calculations. Only by scouring the footnotes and the MD&A [as New Constructs does] can investors get an accurate calculation of ROIC.” – pp. 8, 5th para.
- “The majority of the difference...comes from New Constructs’ machine learning approach, which leverages technology to calculate ROIC by applying accounting adjustments that may be buried deeply in the footnotes across thousands of companies.” – pp. 4, 2nd para.

Superior Stock Ratings

Robo-Analysts’ stock ratings outperform those from human analysts as shown in this [paper](#) from Indiana’s Kelley School of Business. Bloomberg features the paper [here](#).

Key quotes from the paper:

- “the portfolios formed following the buy recommendations of Robo-Analysts earn abnormal returns that are statistically and economically significant.” – pp. 6, 3rd para.
- “Our results ultimately suggest that Robo-Analysts are a valuable, alternative information intermediary to traditional sell-side analysts.” – pp. 20, 3rd para.

Our mission is to provide the best fundamental analysis of public and private businesses in the world and make it affordable for all investors, not just Wall Street insiders.

We believe every investor deserves to know the whole truth about the profitability and valuation of any company they consider for investment. More details on our cutting-edge technology and how we use it are [here](#).



DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first two days after New Constructs issues a report on that security.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs. Copyright New Constructs, LLC 2003 through the present date. All rights reserved.